ISRCTN16842454
Active, not recruiting
未知
Efficacy and safety of convalescent plasma transfusion administered as adjunctive treatment to standard treatment in moderate, severe, and/or critically ill patients with COVID-19
Ministry of Research and Technology/National Research and Innovation Agency (Kementerian Riset dan Teknologi Republik Indonesia)0 sites5 target enrollmentNovember 10, 2020
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Ministry of Research and Technology/National Research and Innovation Agency (Kementerian Riset dan Teknologi Republik Indonesia)
- Enrollment
- 5
- Status
- Active, not recruiting
- Last Updated
- 5 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Confirmed COVID\-19
- •2\. Clinically moderate, severe, and/or critically ill
Exclusion Criteria
- •1\. History of allergy to plasma
- •2\. Patient with an estimated poor prognosis with sofa score \>11, risk of mortality 53%
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Phase 2
Efficacy of convalescent plasma transfusion of COVID-19 survivors on the treatment of respiratory failure of these patientsIRCT20200406046968N2Tabriz University of Medical Sciences30
Unknown
Phase 3
Preemptive Use of Convalescent Plasma for High-risk Patients With COVID-19Covid19Immuno-DeficiencyOld Age; DebilityNCT04836260University Hospital, Geneva100
Completed
Phase 2
Effect of convalescent plasma in COVID-19 patientsHealth Condition 1: B972- Coronavirus as the cause of diseases classified elsewhereCTRI/2020/04/024706Institute of Liver and Biliary Sciences29
Completed
Early Phase 1
Convalescent Plasma for COVID-19 PatientsCOVID 19NCT04516954Vinmec Research Institute of Stem Cell and Gene Technology4
Completed
Phase 3
Effect of convalescent plasma in COVID-19 patientsHealth Condition 1: B972- Coronavirus as the cause of diseases classified elsewhereCTRI/2020/06/025803Institute of Liver and Biliary Sciences400